Raloxifene immediate release tablet for post-menopausal osteoporosis

The book involves a research work towards developing a formulation of anti-osteoporotic drug, which has in-vitro dissolution profile similar to that of the Innovators' formulation. The patents for dosage form of Raloxifene will expire in late future. Hence, our target was to develop a dosage form as that of Innovator product to file an ANDA application. The present study involves the development of a non-infringing formula for an orally administrable immediate release tablet of the anti-osteoporotic drug with reproducible and robust process. The objectives of the research work included (i) formulation and optimization of the coated tablets of Raloxifene with the aid of design of experiment; (ii) enhance dissolution and evaluate release kinetics of drug from the formulation; (iii) comparison of dissolution profiles of developed formulation with innovator product.

Autorentext

La Sra. Binapani Barik, M. pharm, trabaja como profesora asistente en la Facultad de Farmacia de la Universidad de Tecnología y Gestión de Centurión, Odisha. Participa activamente en el desarrollo e investigación de productos farmacéuticos. Su área de investigación se centra en los nanopolímeros, la cronoterapia y los sistemas innovadores de administración de fármacos.